We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
Zhonghua Yi Xue za Zhi [Chinese medical journal] 2003 March 11
OBJECTIVE: To investigate the change of antimicrobial resistance among nosocomial gram-negative bacilli, especially those of Enterobacteriaceae isolated from intensive care units from 1994 to 2001 in China.
METHODS: E test was made to determine the minimal inhibitory concentrations (MIC) of 10 279 isolates of gram-negative bacilli (including 5 829 strains of bacilli of Enterobacteriaceae) from 32 hospitals in China from 1994 to 2001.
RESULTS: The most common pathogens were Pseudomonas aeruginosa; Escherichia coli, Klebsiella spp, Acinetobacter spp. Enterobacter spp, and Stenotrophomonas maltophilia. The most common pathogens in respiratory tract specimens were Pseudomonas aeruginosa (25%), Klebsiella pneumoniae (18%), and Acinetobacter baumanni (11%). The most common pathogens in blood and urine specimens were Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The antibiotic remaining the most active against all of the gram-negative bacilli for 7 years was imipenem (with a susceptibility rate of 87%), followed by cefoperazone/sulbactam (however, with a susceptibility rate decreasing from 86% to 75%), amikacin (75%), ceftazidime (73%), cefepime (72%), and piperacillin/tazobactam (71%). The susceptibility rate of Escherichia coli Klebsiella pneumoniae to imipenem remained 98% with a MIC(90) of 0.5 micro g/ml during the 7 years, much higher than those to amikacin (84%), ceftazidime (83%), cefoperazone/sulbactam (83%), piperacillin/tazobactam (80%), and cefepime (80%). The susceptibility rate of these two species to cefoperazone/sulbactam decreased from 90% in 1996 to 74% in 2001. While the susceptibility to cefotaxime and ceftriaxone decreased from 82% to 57%. The susceptibility rate of Escherichia coli to ciprofloxacin decreased from 54% to 25% and that of Klebsiella pneumoniae to ciprofloxacin decreased from 90% to 75%. The prevalence of extended spectrum beta-lactamases in these two species increased from 11% in 1994 to 34% in 2001. The most active antibiotics against Enterobacter cloacae were imipenem, cefepime, amikacin with the susceptible rates of 95%, 76%, and 70%, respectively; the susceptibility rates of Citrobacter freundii to imipenem, cefepime, amikacin, and cefoperazone/sulbactam were 94%, 80%, 80%, and 78% respectively. Only 40% approximately 60% isolates of Enterobacter cloacae and Citrobacter freundii were susceptible to third-generation cephalosporins.
CONCLUSION: Imipenem remains highly active against Enterobacteriaceae, but the activities of other antibiotics have decreased in recent years.
METHODS: E test was made to determine the minimal inhibitory concentrations (MIC) of 10 279 isolates of gram-negative bacilli (including 5 829 strains of bacilli of Enterobacteriaceae) from 32 hospitals in China from 1994 to 2001.
RESULTS: The most common pathogens were Pseudomonas aeruginosa; Escherichia coli, Klebsiella spp, Acinetobacter spp. Enterobacter spp, and Stenotrophomonas maltophilia. The most common pathogens in respiratory tract specimens were Pseudomonas aeruginosa (25%), Klebsiella pneumoniae (18%), and Acinetobacter baumanni (11%). The most common pathogens in blood and urine specimens were Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The antibiotic remaining the most active against all of the gram-negative bacilli for 7 years was imipenem (with a susceptibility rate of 87%), followed by cefoperazone/sulbactam (however, with a susceptibility rate decreasing from 86% to 75%), amikacin (75%), ceftazidime (73%), cefepime (72%), and piperacillin/tazobactam (71%). The susceptibility rate of Escherichia coli Klebsiella pneumoniae to imipenem remained 98% with a MIC(90) of 0.5 micro g/ml during the 7 years, much higher than those to amikacin (84%), ceftazidime (83%), cefoperazone/sulbactam (83%), piperacillin/tazobactam (80%), and cefepime (80%). The susceptibility rate of these two species to cefoperazone/sulbactam decreased from 90% in 1996 to 74% in 2001. While the susceptibility to cefotaxime and ceftriaxone decreased from 82% to 57%. The susceptibility rate of Escherichia coli to ciprofloxacin decreased from 54% to 25% and that of Klebsiella pneumoniae to ciprofloxacin decreased from 90% to 75%. The prevalence of extended spectrum beta-lactamases in these two species increased from 11% in 1994 to 34% in 2001. The most active antibiotics against Enterobacter cloacae were imipenem, cefepime, amikacin with the susceptible rates of 95%, 76%, and 70%, respectively; the susceptibility rates of Citrobacter freundii to imipenem, cefepime, amikacin, and cefoperazone/sulbactam were 94%, 80%, 80%, and 78% respectively. Only 40% approximately 60% isolates of Enterobacter cloacae and Citrobacter freundii were susceptible to third-generation cephalosporins.
CONCLUSION: Imipenem remains highly active against Enterobacteriaceae, but the activities of other antibiotics have decreased in recent years.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app